EMA Authorised: Olanzapine Glenmark (olanzapine) — Glenmark Arzneimittel GmbH

View source ↗

Summary

Glenmark's olanzapine product has been authorised for schizophrenia and bipolar disorder in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Olanzapine Glenmark (olanzapine)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia;Bipolar Disorder. MAH: Glenmark Arzneimittel GmbH. Decision date: 20/12/2022